1884. Ceftaroline Fosamil (CPT) versus Vancomycin (VAN) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Session: Poster Abstract Session: Clinical Study with New Antibiotics and Antifungals
Saturday, October 7, 2017
Room: Poster Hall CD
Background: Hospital visits for ABSSSIs are rising. Inadequate treatment results in longer stays and increased recurrences. Intravenous (IV) antibiotics (e.g., VAN) are commonly used for ABSSSIs. CPT is approved for ABSSSI, though real world clinical comparative data is limited. The study objective was to compare infection related length of stay (LOSIR) for CPT vs. VAN for ABSSSI.

Methods: We conducted a retrospective, multicenter, propensity-matched cohort study from January 1, 2012 to June 1, 2016 using variable matching ratios. Patients were matched on time to study drug and acute kidney injury (AKI) present on admission (POA). Patients included were adults ≥18 years old with ABSSSI diagnosis and ≥3 clinical signs requiring ≥72 hours CPT or VAN started ≤120h of ABSSSI diagnosis. Patients were excluded if they had osteomyelitis, other infection sources, irremovable hardware, or >120h prior ABSSSI treatment. LOSIR was defined as LOS following ABSSSI diagnosis. Multivariable linear regression examined the independent association between treatment and LOSIR.

Results: A total of 311 patients were matched (119 CPT and 192 VAN). The mean (±standard deviation (SD)) age was 58 (±18) years, 61% Caucasian, 57% male, median (interquartile range (IQR)), Charlson Comorbidity Index (CCI) and LOSIR were 2 (1,3) and 6 (4, 9) days, respectively. Common comorbid conditions were diabetes (38%), peripheral vascular disorders (24%), and chronic pulmonary disease (26%). With regard to ABSSSI, 54% had cellulitis, 48% was lower extremity, 21% had methicillin-resistant Staphylococcus aureus, 64% did not have surgical interventions, 55% were deescalated from IV to oral antibiotics. The median (IQR) of LOSIR for CPT and VAN groups were 5 (4, 8) and 7 (4, 10) days, p = 0.007, respectively. Compared to VAN, CPT was associated with shorter LOSIR after adjusting for ABSSSI type, SIRS criteria, CCI, and AKI POA (p = 0.013).

Conclusion: Compared to VAN, ABSSSI patients treated with CPT had significantly shorter LOSIR. Early CPT use may be considered for patients who need IV antibiotics for ABSSSI treatment to facilitate early discharge. Additional studies are needed to confirm these findings.

Trang D. Trinh, PharmD, MPH, BCPS, AAHIVP1, Evan J. Zasowski, PharmD, MPH, BCPS1, Kimberly Claeys, PharmD, BCPS2, Abdalhamid M. Lagnf, MPH1, Dino Delaportas, MD3, Sandy Estrada, Pharm.D., BCPS (AQ-ID)4, Susan L Davis, PharmD5, Kenneth Klinker, PharmD6, Vanthida Huang, PharmD7, Keith S. Kaye, MD, MPH8, Nicole Bonine, PhD, MPH9, Patrick Gillard, PharmD, MS9 and Michael J. Rybak, PharmD, MPH, PhD1, (1)Anti-Infective Research Laboratory, Department of Pharmacy Practice, Wayne State University, Eugene Applebaum College of Pharmacy & Health Sciences, Detroit, MI, (2)Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD, (3)Mon Health Medical Center, Morgantown, WV, (4)Department of Pharmacy, Lee Memorial Health System, Fort Myers, FL, (5)Pharmacy Practice, Wayne State University, Detroit, MI, (6)UF Health Shands Hospital; University of Florida College of Pharmacy, Gainesville, FL, (7)College of Pharmacy, Midwestern University, Glendale, AZ, (8)University of Michigan Medical School, Ann Arbor, MI, (9)Allergan, plc, Irvine, CA


T. D. Trinh, None

E. J. Zasowski, None

K. Claeys, None

A. M. Lagnf, None

D. Delaportas, Allergan: Speaker's Bureau , Speaker honorarium

S. Estrada, None

S. L. Davis, Allergan: Grant Investigator and Scientific Advisor , Consulting fee and Research grant

K. Klinker, The Medicines Compnay: Scientific Advisor , Consulting fee

V. Huang, None

K. S. Kaye, Allergan: Consultant , Consulting fee

N. Bonine, Allergan: Employee , Salary

P. Gillard, Allergan: Employee , Salary

M. J. Rybak, Allergen: Scientific Advisor , Consulting fee

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.